DEVELOPING NEW THERAPIES FOR METASTATIC CANCERS INCLUIDING HEMATOLOGICAL DISEASE

NucliThera a.s is an R&D company developing targeted short range radionuclides for treating metastatic cancers including lymphoma and leukemia. High-energy alpha- and beta-radiating nuclides are linked to targeting monoclonal antibodies or small molecules. They bind to cancer cells killing them with minimal damage to surrounding healthy tissue.
The NucliThera research team is led by Dr. Roy H Larsen and Professor Emeritus Øyvind S Bruland. They have developed the only alpha-emitting cancer pharmaceutical approved by FDA so far – Xofigo against bone metastases from prostate cancer. Xofigo was acquired by Bayer Healthcare for US$ 2.9 billion in 2014.
More information at Linkedin.

READ MORE

  • RELEASE 4

    Lorem ipsum dolor sit amet consectetur adipiscing elit, sollicitudin purus cras convallis scelerisque diam montes, eu nibh mi tempor orci dignissim. Quis conubia nulla litora condimentum ultrices sodales mus, diam volutpat penatibus iaculis cursus non ultricies venenatis, suspendisse augue curabitur feugiat dapibus proin. Iaculis fames odio mauris id laoreet diam posuere integer risus ad, nascetur…

Leading innovation in Radiotherapy and cancer treatments

OUR MISSION

Our mission is to drive innovation in targeted cancer therapies through advanced radiopharmaceuticals.

OUR SCIENCE

Developing radiopharmaceutical treatments for metastatic cancers.

OUR TEAM

Scientists and specialists dedicated to developing cancer therapies.